RGH-706 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 193 | Prader-Willi syndrome | 1 |
193. Prader-Willi syndrome
Clinical trials : 113 / Drugs : 111 - (DrugBank : 26) / Drug target genes : 48 - Drug target pathways : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05322096 (ClinicalTrials.gov) | September 22, 2022 | 25/3/2022 | Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome | A Randomized, Double-blind, Placebo-controlled, Multi-center, 2-part, Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome | Prader-Willi Syndrome | Drug: RGH-706;Drug: Placebo | Gedeon Richter Plc. | NULL | Recruiting | 17 Years | N/A | All | 176 | Phase 2 | United States;Czechia;France;Italy;Spain |